A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma
2018
OncoTarget
Gemcitabine is a standard treatment for pancreatic adenocarcinoma. Many mechanisms are involved in gemcitabine resistance, such as reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) membrane transporter, deoxycytidine kinase deficiency, and changes in the signal transmission of mitogenactivity protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways. Aim: To evaluate the anti-tumor efficiency of blocking signaling pathways using combined action of
doi:10.18632/oncotarget.25560
pmid:29963262
pmcid:PMC6021353
fatcat:bhsflgvurjbqrk2xylf7nix33u